StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) bonds

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)

Close on Nov 17, 2026Market cap $28.91MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$10.96M
$1.86M due within a year
Net debt
-$15.35M
After $26.31M of cash
Implied interest rate
15.98%
FY2026 interest ÷ average debt
Interest coverage
-4.4×
FY2026 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Jun 30, 2026

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Aytu BioPharma's 10-K for the period ended Jun 30, 2026

IssueCouponAmount issued
Eclipse Term LoanFloating + 7.00%$13.00M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeAvailable
Incremental Advance$1.50M–
Revolving Credit Facility$14.50M$5.20M

See a number that looks wrong?